KYNTRA BIO, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- KYNTRA BIO, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00.
- KYNTRA BIO, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00.
- KYNTRA BIO, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $0.00.
- KYNTRA BIO, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was -$46.00K.
- KYNTRA BIO, INC. stock issued during period, value, new issues for fiscal 2025 was -$46.00K.
- KYNTRA BIO, INC. stock issued during period, value, new issues for fiscal 2023 was $48.41M.
- KYNTRA BIO, INC. stock issued during period, value, new issues for fiscal 2017 was $470.23M.
- KYNTRA BIO, INC. stock issued during period, value, new issues for fiscal 2014 was $151.83M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$46.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | |
| 2025-03-31 | -$46.00K 10-Q · filed 2026-05-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $48.41M 10-K · filed 2025-03-17 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $17.28M 10-Q · filed 2024-08-06 | |
| 2023-03-31 | $31.13M 10-Q · filed 2024-05-06 | |
| 2017-12-31 | $470.23M 10-K · filed 2020-03-02 | |
| 2014-12-31 | $151.83M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |